MTTI currently has two products in development: Lu-177 EBTATE, which targets somatostatin receptors type 2 in a variety of neuroendocrine tumors, and Lu-177 EBRGD for integrin-expressing cancers in glioblastoma multiforme and non-small cell lung cancer.

The new radiotracers bind reversibly to circulating serum albumin, which enhances radiotherapeutic circulation half-life and delivers higher accumulation to targeted tumors, according to studies.